Brickell Biotech, Inc. is a clinical-stage pharmaceutical companystriving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases. Brickell’s pipeline combines a potential best-in-class, late clinical-stage program for hyperhidrosis with a novel, cutting-edge platform with broad potential in autoimmune and neuroinflammatory disorders.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can meaningfully benefit patients who are suffering from debilitating diseases that are underserved by available therapies.
Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
Lake Street Capital Partners 5th Annual Best Ideas Growth Conference